Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of the Effectiveness and Safety of the MEK 1/2 Inhibitor (MEKi) Koselugo (Selumetinib) in Pediatric Patients With Symptomatic, Inoperable, Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (PN)

NCT06175637 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06175637
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06175637 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of the Effectiveness and Safety of the MEK 1/2 Inhibitor (MEKi) Koselugo (Selumetinib) in Pediatric Patients With Symptomatic, Inoperable, Neurofibromatosis Type 1 (NF1)-Associated Plexiform Neurofibromas (PN)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
December 20, 2023
Completion date
June 30, 2027
Enrollment
409 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

neurofibroma, plexiform